FDA Approves First mRNA Flu Vaccine for Older Adults
Washington, Friday, 7 August 2026.
The U.S. FDA approved Moderna’s mFlusiva, the first mRNA flu shot for adults aged 50 and older. Clinical trials show it is 27% more effective than standard shots.
Regulatory Milestone for Moderna
The U.S. Food and Drug Administration has officially approved Moderna’s mRNA-based influenza vaccine, mFlusiva, for adults aged 50 and older [2][3]. This regulatory decision, finalized on 6 August 2026, marks the first approval of an mRNA technology flu vaccine by the agency [1][4]. The vaccine, designated mRNA-1010, represents a significant expansion of Moderna’s commercial portfolio beyond its COVID-19 products [5]. Analysts indicate this approval serves as a critical growth driver as the company diversifies its post-pandemic offerings [1]. The approval encompasses adults aged 50 to 64 under full approval, while those 65 and older received accelerated approval pending further data [2][5].
Efficacy and Clinical Performance
In late-stage clinical trials involving over 40,000 participants, mFlusiva demonstrated approximately 27% higher effectiveness compared to standard influenza vaccines [3][6]. For the demographic aged 65 and older, the vaccine generated a stronger immune response than existing high-dose flu vaccines currently available [6]. Despite the positive efficacy data, the FDA requires Moderna to conduct an additional clinical trial for the 65+ age group to verify clinical benefits [3][5]. Common side effects reported include injection site reactions, fatigue, and headache, consistent with other mRNA vaccine profiles [5].
Manufacturing Speed and Regulatory Challenges
A key advantage of the mRNA platform is the significantly faster production timeline compared to traditional egg-based methods [1]. While conventional vaccine manufacturing requires approximately 6 months from strain selection, mRNA technology reduces this window to 2 to 3 months [3][6]. This reduction represents a potential decrease in production lead time of 50 percent when comparing the upper bound of the mRNA timeline to traditional methods [6]. However, the rollout faces regulatory hurdles; the CDC’s Advisory Committee on Immunization Practices (ACIP) is currently blocked from convening by a federal judge [3][6]. Without ACIP recommendations, insurance coverage for the vaccine remains uncertain despite FDA approval [6].
Political Context and Market Availability
The approval process occurred amidst heightened scrutiny of mRNA technology by federal health leadership [3]. HHS Secretary Robert F. Kennedy Jr. had previously canceled approximately $500 million in mRNA research funding in 2025, citing a need for heightened scientific scrutiny [3][6]. The FDA initially refused to review Moderna’s application earlier in 2026 before reversing the decision one week later following pressure from infectious disease experts [2][6]. Moderna expects mFlusiva doses to be available for the upcoming 2026–2027 respiratory virus season [4][5]. Regulatory submissions are also under review in the European Union, Canada, and Australia [5].